Is Hers weight loss legit? The FDA letter and the Novo Nordisk lawsuit, explained
Hers is a real, licensed telehealth company owned by an NYSE-listed parent — that part isn't in question. What's worth slowing down for is a September 2025 FDA warning letter over how it marketed compounded semaglutide, and the Novo Nordisk patent lawsuit it settled in March 2026 — both real, both resolved, and both changing what you'd actually be prescribed today.
Hers is one of the most accessible, lowest-friction ways to start a doctor-supervised weight-loss plan from home, and for most women it simply works: a licensed clinician, a prescription, and medication at the door in days. It is backed by Hims & Hers Health, a company listed on the NYSE — legitimacy is not the question. The two things worth understanding before you join: the weight-loss line now centers on brand-name GLP-1s — the Wegovy pill (from $149/mo medication), the Wegovy pen (from $199/mo), and the Zepbound vial (from $299/mo, rising with dose) — plus a low-cost oral kit that is not a GLP-1; and the monthly membership is billed separately from the medication. Compounded semaglutide is no longer the default offer — after the March 2026 Novo Nordisk partnership, Hers stopped advertising it and keeps it only as a narrow clinical exception. Best fit for a woman who wants convenience and clarity on which product she is actually buying.
What you will actually pay
The care platform — billed apart from any drug
Lowest-cost entry into a brand-name GLP-1
The injectable most clinical trials studied
Dual-action GLP-1/GIP for higher weight-loss targets
Needle-free, lowest cost, modest effect
No longer the default — kept only where a clinician deems it necessary
Estimated all-in cost: ~$3,600–$5,400/yr for common branded plans (Wegovy pill or pen + membership); higher for top-dose Zepbound
- ✓ Legitimate and established — the women's brand of Hims & Hers Health (NYSE: HIMS), licensed clinicians in all 50 states, registered pharmacies
- ✓ Genuinely fast and low-friction — online intake in minutes, clinician review, medication shipped to your door, no in-person visit and no video call required
- ✓ Brand-name GLP-1s at well-below-retail cash prices — the Wegovy pill from $149/mo medication, the pen from $199/mo, far less than the $1,000+ retail sticker
- ✓ A real range of FDA-approved options now — the Wegovy pill and pen, the Zepbound vial, plus a non-GLP-1 oral kit, after a March 2026 Novo Nordisk agreement
- ✓ Care is bundled in — the membership includes clinician messaging, ongoing check-ins, and nutrition guidance, not just a script
- ⚑ The membership is billed separately from the medication, so the all-in monthly cost is higher than the headline drug price — and cancelling one does not cancel the other
- ⚑ Medication pricing climbs with dose — entry Zepbound starts around $299/mo on top of membership and high doses run materially higher, so price the dose you expect to need
- ⚑ Compounded semaglutide is no longer a price-led default — Hers stopped advertising it in March 2026 and keeps it only as a narrow clinical exception; the FDA had also sent a warning letter in September 2025 over how it was marketed
- ⚑ It is a weight service, not a menopause service — no hormone therapy and a protocol that does not adjust for a midlife hormonal body
- ⚑ No insurance accepted, and lab work can be a separate line, so price the full picture before you join
Type "is Hers legit" into a search bar and you'll find two camps: people who got a prescription in a day and never think about it again, and people who found a warning letter or a lawsuit headline and stopped cold. Both reactions are understandable, and neither is the full picture. This page walks through the regulatory record in order — what's a real company fact, what's a real caution, and what actually changed once the dust settled.
Is Hers an outright scam, or a real company?
Start with the boring, verifiable part, because it settles the scam question outright. Hers is the women's brand of Hims & Hers Health, Inc., a company listed on the New York Stock Exchange under the ticker HIMS. It isn't a shell site or a drop-shipping operation — it prescribes through US-licensed clinicians in all fifty states and fills prescriptions through registered pharmacies, the same regulatory scaffolding any telehealth prescriber has to operate under. It also carries a BBB accreditation dating back to February 2018, with an A+ rating attached to that file.
None of that means every experience with Hers is smooth, and the rest of this page is about the parts that genuinely deserve scrutiny. But "is it a scam" and "is every part of it beyond reproach" are different questions. The first one has a clear answer: no. It's a licensed, publicly traded, accredited telehealth business.
What did the FDA warning letter actually say?
This is the part worth reading precisely rather than summarizing. On September 9, 2025, the FDA sent a warning letter to Hims & Hers Health, Inc., doing business as Hers, after reviewing the forhers.com website. The agency didn't allege the medication itself was unsafe. It cited specific marketing language — phrases like "weekly injectable GLP-1 with the same active ingredient as Ozempic" and "clinically proven ingredients" — as false or misleading under sections 502(a) and 502(bb) of the Food, Drug, and Cosmetic Act, on the grounds that this wording implied the compounded product was equivalent to an FDA-approved drug when it was not.
A near-identical letter went to the men's-branded hims.com site the same day, and around the same period the FDA sent similar warning letters to a number of other telehealth sellers of compounded GLP-1s — this reads as part of a broader industry sweep, not a Hers-specific singling-out, though the exact count is worth confirming rather than taking as settled. The distinction that matters for a reader: the letter was about how the product was described, not a finding that the compounded drug itself was dangerous. Compounding is legal; claiming equivalence to a brand-name, FDA-approved medicine without that approval is what the FDA flagged.
What was the Novo Nordisk lawsuit about, and how did it end?
The lawsuit has a longer arc than the headline suggests. Hims & Hers and Novo Nordisk briefly partnered in spring 2025 to offer genuine Wegovy through the platform; that arrangement fell apart within months and was terminated. Hims & Hers kept selling compounded semaglutide — including, reporting indicates, a low-cost oral version — and on February 9, 2026, Novo Nordisk filed a patent infringement suit in federal court in Delaware, alleging the compounded products infringed a patent covering semaglutide's molecular structure — the same active ingredient in Wegovy and Ozempic.
The suit didn't run its course. On March 9, 2026, the two companies announced a settlement: Novo Nordisk voluntarily dismissed the case without prejudice, and in exchange Hims & Hers agreed to stop mass-marketing and advertising compounded semaglutide. In return, Novo Nordisk gave Hers the right to sell its own FDA-approved medicines directly — the Wegovy pen and the newer Wegovy pill — on the platform. Hims & Hers stock jumped sharply on the news, which tells you how much the deal changed the company's product mix going forward, not just its legal exposure.
Are Hers weight-loss medications themselves safe?
This is where it's easy to conflate two separate things: the company's legitimacy, and the regulatory status of a specific product. Compounded semaglutide is not itself an unsafe molecule — it's the same active ingredient studied in the branded trials — but a compounded version is mixed by a pharmacy rather than manufactured and reviewed by the FDA as a finished product, so it doesn't carry the same consistency oversight. That's the gap the warning letter was about, and it's the gap the settlement narrowed.
What you'd actually be prescribed today looks different from a year ago. Since the March 2026 Novo Nordisk settlement, Hers has pulled back from advertising compounded semaglutide as a default option and now centers its weight-loss line on the brand-name, FDA-approved Wegovy pill and pen, alongside a lower-cost, non-GLP-1 oral kit built from older generics. (A separate, unrelated deal with Eli Lilly also brought the Zepbound vial onto the platform — that access didn't come from the Novo settlement.) Compounded semaglutide still exists on the menu, but only as a narrow clinical exception a prescriber decides on case by case, not the price-led entry point it used to be. If a version-specific safety question matters to you, ask directly which product you're being offered before you pay, because the site no longer defaults to the one the FDA had concerns about.
What do BBB and Trustpilot actually show?
The BBB file for Hims & Hers Inc. carries an A+ rating and accreditation dating to 2018, and a company review of that file in September 2025 noted that the complaints on record concentrate on cancelling orders and refund requests — not on product safety or fraud. Trustpilot tells a similar, if noisier, story: forhers.com sits at an "Average" rating in the mid-3s out of 5 across several thousand reviews, with the split falling along predictable lines. People who got a fast prescription and easy shipping rate it well; people fighting a charge or a slow support reply rate it poorly. Both platforms point the same direction: this is a company where the product mostly works, and the friction lives in billing and support responsiveness, not in the medicine.
What billing and subscription complaints are already on record?
If there's a genuine pattern in the complaint record, it's a mechanical one, and it's worth naming plainly so it doesn't surprise you.
- Two separate subscriptions. The membership and the medication renew on their own schedules, and cancelling one does not cancel the other — a recurring theme in complaints is being billed for the half someone forgot.
- A tight cancellation window. Avoiding the next charge generally requires cancelling roughly two days (about 48 hours) before your renewal date, which is easy to miss if you're not watching the calendar.
- Prepaid multi-month plans are largely non-refundable, and medication that has already shipped isn't refundable at all — so an early change of mind can be costly.
- Shipping and refill delays show up often enough in reviews to be a real theme, particularly for anyone titrating a dose on a schedule.
- Slow customer support response times are the single most repeated frustration, especially when the thing someone is trying to stop is an active charge.
None of that is unique to Hers among subscription telehealth brands, but it's consistent enough across the BBB, Trustpilot, and ConsumerAffairs records to treat as a known quantity rather than bad luck. Read the full Hers cost breakdown before you sign up, and put both cancellation dates on your calendar the day you start.
Bottom line: who should trust Hers, and who should look elsewhere
Put the pieces together and the picture is coherent, not contradictory. "Legit" — licensed clinicians, registered pharmacies, a publicly traded parent, an accredited BBB file — was never actually in dispute, and the FDA letter and the Novo lawsuit don't change that answer. What they establish instead is a specific, resolved caution: for a period, Hers marketed a compounded product with language regulators found misleading, and it fought a patent claim over that same product before settling by agreeing to stop pushing it and adding the brand-name alternative instead. That's a company correcting course under real external pressure, not one hiding a fraud — trust the license and the structure, and be precise about which specific product you're buying, since that's the layer where the actual regulatory weather happened.
If you want fast, cash-pay access to a doctor-supervised weight-loss plan, are comfortable managing two separate subscriptions carefully, and specifically want the brand-name Wegovy or Zepbound that Hers now offers post-settlement, this is a legitimate and reasonable place to start. If you're drawn only by the lowest possible price and would have chosen compounded semaglutide specifically, know that it's no longer the default here — confirm exactly what you'd be prescribed before you commit. And if a slow support line or a missed cancellation window would genuinely upset you, build in a calendar reminder from day one; that's where the real friction in this brand's record lives, not in whether it's a real company.
Frequently asked questions
Is Hers legit?+–
Yes. Hers is the women's brand of Hims & Hers Health, a telehealth company listed on the New York Stock Exchange (NYSE: HIMS), operating through US-licensed clinicians and registered pharmacies with real prescriptions and clinical oversight. It carries an A+ Better Business Bureau accreditation. The historical asterisk is the compounded semaglutide it used to lead with: that version was never FDA-approved as a finished drug, and the FDA sent a warning letter in September 2025 over how it was marketed. Hers has since moved to brand-name Wegovy and Zepbound and stopped advertising compounded semaglutide as of March 2026.
What does Hers weight loss actually cost?+–
Two lines, not one. The medication runs from about $149/mo for the Wegovy pill, from $199/mo for the Wegovy pen, and from $299/mo for the entry Zepbound vial (rising with dose); the non-GLP-1 oral kit starts around $69/mo. On top of that sits the membership — about $39 the first month, then $149/mo — which is billed separately. So a common all-in lands near $298/mo for the Wegovy pill, ~$348 for the pen, and ~$448 for entry Zepbound; the first month is lower (around $188) and high-dose Zepbound runs higher. Prices shift often; confirm the current numbers at checkout.
Is the Hers weight-loss medication real, FDA-approved GLP-1?+–
Yes — the current lineup is brand-name, FDA-approved medication: the Wegovy pill and pen (semaglutide) and the Zepbound vial (tirzepatide), all manufactured by their makers rather than compounded. The lower-priced oral kit is a different thing entirely: a clinician-chosen combination of older medications (metformin, bupropion, naltrexone), not a GLP-1. Hers used to lead with compounded semaglutide, but after its March 2026 Novo Nordisk agreement it stopped advertising it and now keeps it only as a narrow clinical exception, not a price-led default.
Does Hers take insurance?+–
No. Every plan is cash-pay. If insurance coverage for a GLP-1 is your priority, a brand-name prescription through your own clinician is usually the better starting point — though Hers can be cheaper out of pocket than an uncovered brand-name drug.
Is Hers good for menopause or perimenopause weight gain?+–
It can help with the weight, but it is not a menopause service. Midlife weight gain is often driven by falling estrogen — visceral fat rises and insulin sensitivity drops — and Hers does not offer hormone therapy or adjust its protocol for that. If the wider hormonal picture matters to you, pair a GLP-1 decision with menopause-literate care rather than treating the number on the scale in isolation.
How do I cancel Hers, and is it hard?+–
It is more involved than signing up. The membership and the medication are separate subscriptions, so you have to cancel both — the most common complaint on file is being billed for the half people forgot. Cancel each a few days before your renewal date and keep a screenshot of both confirmations. Note that prepaid multi-month plans are generally not refundable, so time any cancellation around your billing cycle.